Parkinson’s disease (PD) is an age-related incurable disorder observed in 3% of persons 65+, and 10% of those 80+, making it one of the more common neurological disorders of later life. In Australia, 1 in every 340 people lives with this devastating condition. A 4% per annum growth in the prevalence of PD is projected for the next 20 years. The prevalence of anxiety in PD exceeds 50%, and it is a major contributor to a poor quality of life of patients and caregivers. However, anxiety is poorly identified in PD. There is a paucity of clinical trials primarily focussed on treating anxiety, and there are no evidence based effective and safe pharmacological treatment for anxiety in PD.                                                                                                               

To complicate matters further, anxiety in PD presents with unique and complex symptomatology, which must be understood and addressed if intervention is to be effective. There is an urgent need for empirically validated interventions targeting PD-specific anxiety symptoms for successful treatment.                                 

The objective of this study is to improve assessment and treatment of anxiety in PD. This study will also focus on caregivers.